SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-126425
Filing Date
2024-05-01
Accepted
2024-05-01 08:40:55
Documents
13
Period of Report
2024-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d65915d8k.htm   iXBRL 8-K 33489
  Complete submission text file 0001193125-24-126425.txt   162144

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA alrn-20240501.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE alrn-20240501_lab.xml EX-101.LAB 18757
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE alrn-20240501_pre.xml EX-101.PRE 11714
17 EXTRACTED XBRL INSTANCE DOCUMENT d65915d8k_htm.xml XML 3808
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Aileron Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

IRS No.: 134196017 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38130 | Film No.: 24900228
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)